Evidence map›Paper›PMID 29844451›Full record

ArticleScientific reports2018

Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice.

Xiaochen Chen, Jin Ma, Tony Kwan, Elisabeth G D Stribos, A Lianne Messchendorp, Yik W Loh, Xiaoyu Wang, Moumita Paul, Eithne C Cunningham, Miriam Habib and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Damage-Associated Molecular Patterns and Pattern Recognition Receptors in the Podocyte.Journal of the American Society of Nephrology : JASN · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. [Quercetin ameliorates diabetic kidney injury in rats by inhibiting the HMGB1/RAGE/NF-κB signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Experimental and therapeutic medicine · 2023
    Article
  16. Review
  17. Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease.International journal of biological sciences · 2023
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Xiaochen ChenKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Jin MaKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Tony KwanKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Elisabeth G D StribosKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
A Lianne MesschendorpKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Yik W LohKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Xiaoyu WangKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Moumita PaulTransplantation Immunobiology Group, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Eithne C CunninghamTransplantation Immunobiology Group, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Miriam HabibTransplantation Immunobiology Group, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Ian E AlexanderGene Therapy Research Unit, Children's Medical Research Institute and The Children's Hospital at Westmead, Westmead, NSW, Australia.
Alexandra F SharlandTransplantation Immunobiology Group, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Steven J ChadbanKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.ORCID 0000-0002-0527-898X
Huiling WuKidney Node Laboratory, Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia. huiling.wu@sydney.edu.au.
The University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activation of TLR2 or TLR4 by endogenous ligands such as high mobility group box 1 (HMGB1) may mediate inflammation causing diabetic kidney injury. We determined whether blockade of HMGB1 signaling by: (1) supra-physiological production of endogenous secretory Receptor for Advanced Glycation End-products (esRAGE), a receptor for HMGB1; (2) administration of HMGB1 A Box, a specific competitive antagonist, would inhibit development of streptozotocin induced diabetic nephropathy (DN). Wild-type diabetic mice developed albuminuria, glomerular injuries, interstitial fibrosis and renal inflammation. Using an adeno-associated virus vector, systemic over-expression of esRAGE afforded significant protection from all parameters. No protection was achieved by a control vector which expressed human serum albumin. Administration of A Box was similarly protective against development of DN. To determine the mechanism(s) of protection, we found that whilst deficiency of TLR2, TLR4 or RAGE afforded partial protection from development of DN, over-expression of esRAGE provided additional protection in TLR2

Indexed as

AlbuminuriaAnimalsDiabetes Mellitus, ExperimentalDiabetic NephropathiesDisease Models, AnimalFemaleGlycation End Products, AdvancedHEK293 CellsHMGB1 ProteinHumansInflammationKidneyMaleMiceMice, Inbred BALB CMice, Inbred C57BLesRAGE protein, humanGlycation End Products, AdvancedHMGB1 ProteinHMGB1 protein, mouseReceptor for Advanced Glycation End ProductsRecombinant ProteinsTlr2 protein, mouseTlr4 protein, mouseToll-Like Receptor 2Toll-Like Receptor 4

Identifiers

PMID29844451
PMCPMC5974129
OpenAlexW2805557676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.